Tissue Regenix: On pathway to sustainability

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX’s strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023.

  • Strategy: Tissue Regenix is building an international regenerative medicine business around its proprietary technology platforms, underpinned by compelling clinical outcomes. Phase 1 of its manufacturing capacity expansion programme came on-stream in 2021 to satisfy demand from distribution partners for its innovative products.
  • 2021 results: Sales in fiscal 2021 were marginally ahead of our forecasts, at $19.75m, up 20% from $16.47m in 2020. The leverage effect of a strong BioRinse sales performance (+33%) saw a marked reduction in EBIT losses in 2H’21. Gross cash at the period-end was $7.7m.
  • Outlook: The 2021 performance was achieved despite the continuing impact of COVID-19 and some unforeseeable headwinds; this augurs well for the future. Progress is forecast to continue in 2022, resulting in 22% sales growth, which will drive margin expansion towards profitability by the end of 2022.
  • Risks: Early signs of recovery in the number of elective surgeries in the US were dented by the delta variant, and the emergence of another variant remains a possibility. Forecasts suggest that TRX is nearing profitability and cashflow breakeven, which would eliminate any lingering concerns about the need for a capital increase.
  • Investment summary: Tissue Regenix has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme has comforted distribution partners and provided positive momentum. We believe TRX is well-positioned to deliver strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $120m/£92m.

sustainability/?dm_i=49CL,1AR6E,6NAI95,5ZRZV,1#report-download" rel="noreferrer noopener">DOWNLOAD THE FULL REPORT

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Analyst Mark Thomas of Hardman & Co breaks down how the Group is building long-term shareholder value by expanding specialist lending, attracting new banking clients, and scaling its wealth management business.
    Discover insights from analyst Mark Thomas on NB Private Equity Partners plc (LON:NBPE) as he discusses key trends, capital allocation, and market dynamics.
    Mark Thomas discusses the firm’s revised strategy, how it’s navigating interest rate expectations, and what a potential Trump 2.0 administration could mean for NBPE
    Discover the latest insights on H&T Group plc's strong 2024 performance, featuring impressive growth in profits, retail sales, and pawnbroking demand.
    Mark Thomas breaks down why the momentum in pawnbroking, value retail, forex, gold trading, and store expansion could make H&T a standout in a tight consumer environment
    The spotlight is on a trading update that surpassed expectations and a strategy that’s tightening focus on growth and guest experience

      Search

      Search